DDInter540 DDInter1082
A carbonic anhydrase inhibitor that is used in the treatment of glaucoma.
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM). It is sold by Sanofi-Aventis under the brand name Adlyxin in the US and Lyxumia in the EU. Adlyxin recieved FDA approval July 28, 2016.
Diclofenamide {u} (Compound) resembles {v} (Compound) Hydrochlorothiazide
Diclofenamide {u} (Compound) resembles {v} (Compound) Chlorothiazide
Diclofenamide {u} (Compound) treats {v} (Disease) glaucoma
Diclofenamide {u} (Compound) binds {v} (Gene) CA2
Diclofenamide {u} (Compound) upregulates {v} (Gene) PLCB3
Diclofenamide {u} (Compound) is included by {v} (Pharmacologic Class) Sulfonamides
Diclofenamide {u} (Compound) downregulates {v} (Gene) CEBPB
Diclofenamide {u} (Compound) causes {v} (Side Effect) Tension
Diclofenamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tetracycline
Diclofenamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magnesium hydroxide
Diclofenamide (Compound) resembles Hydrochlorothiazide (Compound)
Diclofenamide (Compound) resembles Chlorothiazide (Compound)
Diclofenamide (Compound) treats glaucoma (Disease)
Diclofenamide (Compound) binds CA2 (Gene)
Diclofenamide (Compound) upregulates PLCB3 (Gene)
Diclofenamide (Compound) is included by Sulfonamides (Pharmacologic Class)
Diclofenamide (Compound) downregulates CEBPB (Gene)
Diclofenamide (Compound) causes Tension (Side Effect)
Diclofenamide may cause a minor interaction that can limit clinical effects when taken with Tetracycline
Diclofenamide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide